Management of Multidrug-Resistant HIV

Ryan Haumschild, PharmD, MS, MBA, opens a panel discussion surrounding the incidence and prevalence of multidrug-resistant (MDR) HIV.

Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV.

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

Therapy adjustments in MDR HIV are explored by Dr Sension.

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

Key opinion leaders highlight barriers to MDR HIV treatment adherence.

Dr Sension underlines the value of CD4 recovery from payer and clinician perspectives.

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.